Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / Jan / P-tau: Predictor and Protector in Alzheimer’s
Clinical Translational Science Mass Spectrometry News and Research

P-tau: Predictor and Protector in Alzheimer’s

A new diagnostic marker and neuroprotective shield in neurodegenerative disease

By Jessica Allerton 01/28/2025 1 min read

Share

Credit: Adobe Stock

A recent study in Cell Reports highlights the diagnostic potential of phosphorylated tau (p-tau) in Alzheimer’s disease (AD) as well as its role in defending against herpes simplex virus-1 (HSV-1). Researchers from the University of Pittsburgh and Hebrew University of Jerusalem employed advanced imaging techniques and in vitro models to investigate the interactions between p-tau and HSV-1, highlighting implications for innate immune responses in neurodegenerative diseases.

HSV-1 DNA and proteins were detected in human brain samples from AD patients – establishing a direct HSV-1 and p-tau link. Mass spectrometry and western blotting correlated increased levels of viral proteins (including ICP27) with disease severity.

Additionally, the researchers found that, in iPSC-derived brain organoids, HSV-1 infection activates the cGAS-STING-TBK1 pathway, leading to tau phosphorylation. Moreover, p-tau reduced viral protein expression and decreased neuronal death from 64 percent to 7 percent.

This study positions p-tau as both a diagnostic marker and a key player in neuronal defense against HSV-1. Diagnostic tools leveraging p-tau levels and colocalization with viral proteins could enhance early detection and disease monitoring.

Finally, the research points to an interesting therapeutic angle; could targeting the cGAS-STING-TBK1 pathway harness p-tau’s protective mechanisms while mitigating its long-term pathological effects?

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Associate Editor, The Analytical Scientist

More Articles by Jessica Allerton

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.